Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 78

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 78
---
 $4.75 per share; |

| ● | 560,171 shares of common stock issuable upon conversion of the 1,039 shares of the Company’s Series A Preferred Stock outstanding, at a conversion price equal to $2.25 per share; and |

| ● | 2,158,658 shares of common stock reserved for issuance under the Plan. |

45

Dilution If you invest in our common stock and/or Pre-Funded Warrants in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share of our common stock underlying the Units and the pro forma as adjusted net tangible book value per share of our common stock after this offering. Our net tangible book value as of September 30, 2024, was $(6,834,620), or approximately $(0.68) per share of our common stock. Net tangible book value per share is equal to our total tangible assets less our mezzanine equity and total liabilities, divided by the number of shares of our outstanding common stock. Our pro forma net tangible book value (deficit) as of September 30, 2024, after Vivus Adjustments was $(8,972,238) or approximately $(0.90) per share. After giving further effect to (i) the sale of Units in this offering at the public offering price of $0.24 per share, and after deducting the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the cash exercise of the Series Warrants issued in this offering and assuming that the Pre-Funded Warrants issued in this offering are exercised, and (ii) the Pro Forma Adjustments, our pro forma as adjusted net tangible book value (deficit) per share after giving effect to this offering would have been $(515,238) or $(0.01) per share of common stock. This represents an immediate increase in as adjusted net tangible book value of $0.89 per share to our existing stockholders, and an immediate dilution of $0.25 per share to new investors purchasing securities in this offering at the public offering price. The following table illustrates this dilution on a per share basis:

| public offering price per share and accompanying Series Warrants                                                                                           
 Historical net tangible book value per share as of September 30, 2024                                                                                      | ​ | ​ 
 ​ | (0.68) | ​ | ​ |  0.24